ABSTRACT
During the past three decades patients with hematological malignancies, particularly chronic myeloid leukemia (CML), have been served well by clinical and laboratory research and the unraveling of some of the molecular mechanisms that underlie malignant diseases has paved the way to defi ning potential specifi c targets for treatment. The success of such treatments, epitomizing the “bench-to-bedside” paradigm, has increased optimism for their broader application in cancer medicine.
